title: Rifapentine for the treatment of latent tuberculosis.
abstract: The goal of this article is to review the use of rifapentine in the treatment of latent tuberculosis infection (LTBI). Controlling LTBI is an important part of the global strategy to end the spread of tuberculosis. Rifapentine's potent sterilizing effect against Mycobacterium tuberculosis combined with its long half-life make it an attractive LTBI treatment option. Areas covered: A systematic literature search of Pubmed using the terms 'rifapentine' and 'tuberculosis' was performed. Articles identified were cross-referenced for other relevant publications. The mechanisms of action and resistance, pharmacokinetic and pharmacodynamics, potential drug interactions and side effects are discussed. Expert commentary: Rifapentine in combination with isoniazid for twelve weeks is the best available option for treating latent TB in the majority of patients in the United States due to its favorable safety profile and the increased likelihood of completing therapy. Currently, rifapentine is not registered or available in other countries.
authors.affiliation: a Department of Pharmacotherapy and Translational Research, College of Pharmacy , University of Florida , Gainesville , FL , USA.|b Infectious Disease Pharmacokinetics Laboratory , University of Florida , Gainesville , FL , USA.
authors.forename: Eric F
authors.initials: EF
authors.lastname: Egelund
authors.affiliation: a Department of Pharmacotherapy and Translational Research, College of Pharmacy , University of Florida , Gainesville , FL , USA.|b Infectious Disease Pharmacokinetics Laboratory , University of Florida , Gainesville , FL , USA.|c Emerging Pathogens Institute , University of Florida , Gainesville , FL , USA.
authors.forename: Charles A
authors.initials: CA
authors.lastname: Peloquin
keywords: Latent tuberculosis; mycobacterium tuberculosis; rifamycins; rifapentine